Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer

Table 4 Polymorphisms of matrix metalloproteinases in hepatocellular carcinoma

Gene	SNP	Reference	Ethnicity	Case/control	Parameter	Results	Parameter OR	OR	95% CI	P value
MMP-1	-1607 1G/2G	Zhai[80]	Chinese	434/480	Cancer risk	No difference in cancer risk
		Okamoto[78]	Japanese	95/83	Cancer risk	Increased risk of HCC in 2G/2G				0.002
					Clinicopath. par.	No correlation with any clinicopath. par.
					Survival	No difference in survival
		Okamoto[79]	Japanese	92/170	Cancer risk	No difference in cancer risk
					Survival/clinicopath. par.	No difference in survival/clinicopath. par.
MMP-2	-735 C/T	Zhai[80]	Chinese	434/480	Cancer risk	No difference in cancer risk
					Cancer risk	No difference in cancer risk
MMP-2	-1306 C/T	Zhai[80]	Chinese	434/480	Cancer risk	No difference in cancer risk
		Wu[82]	Chinese	93/0	HCC recurrence after LTx	More CC in recurrence group	CT vs CC	0.42	0.18-0.99	< 0.05
MMP-3	-1171 5A/6A	Zhai[80]	Chinese	434/480	Cancer risk	No difference in cancer risk
		Okamoto[78]	Japanese	95/83	Cancer risk	No difference in cancer risk
					HCC diameter at diagnosis	Larger diameter in 5A allele carriers
					Survival	Decreased survival in 5A allele carriers
		Okamoto[79]	Japanese	92/170	Cancer risk	Increased cancer risk in 5A allele carriers
					Survival/clinicopath. par.	Decreased survival in 5A allele carriers				0.035
MMP-7	-181 A/G	Qiu[81]	Chinese	434/480	Cancer risk	No difference in cancer risk
MMP-8	-799 C/T	Qiu[81]	Chinese	434/480	Cancer risk	No difference in cancer risk
MMP-9	-1562 C/T	Zhai[80]	Chinese	434/480	Cancer risk	No difference in cancer risk
		Wu[82]	Chinese	93/0	HCC recurrence after LTx	No difference in HCC recurrence
		Okamoto[78]	Japanese	95/83	Cancer risk	No difference in cancer risk
					Differentiation grade	Differentiation worse in T allele carriers		0.03
					Survival	No difference in survival
		Okamoto[79]	Japanese	92/170	Cancer risk	No difference in cancer risk
					Survival/clinicopath. par.	No difference in survival/clinicopath. par.
MMP-12	-82 A/G	Zhai[80]	Chinese	434/480	Cancer risk	No difference in cancer risk
MMP-13	-77 A/G	Zhai[80]	Chinese	434/480	Cancer risk	No difference in cancer risk
MMP-21	C572T	Qiu[81]	Chinese	434/480	Cancer risk	No difference in cancer risk
TIMP-2	-418 G/C	Okamoto[83]	Japanese	92/70	Cancer risk HCC	No difference in cancer risk
					Survival	No difference in survival

SNP: Single nucleotide polymorphism; LN: Lymph node; Clinicopath. par.: Clinicopathological parameters; OR: Odds ratio; 95% CI: 95% confidence interval; HCC: Hepatocellular carcinoma; LTx: Liver transplantation.